Prior to April 2022, cases of the monkeypox virus infecting people outside of Africa's endemic regions were infrequent. Cases are currently happening everywhere. Infection outcomes, risk factors, clinical presentation, and transmission are all poorly understood.Monkeypox cases in humans are uncommon outside of west and central Africa. There are no approved treatments, no information on viral kinetics or the length of viral shedding. Two oral medications, brincidofovir and tecovirimat, have received approval for the treatment of smallpox and have shown effectiveness in animal tests against monkeypox. Our goal was to characterise the longitudinal clinical course of monkeypox in a setting with a high level of income, together with viral dynamics and any negative side effects from innovative antiviral treatments.To stop the spread of the Monkey pox virus infection during outbreaks, community education and training are required.

Monkey pox virus, Aventis Pasteur Smallpox Vaccine, Tecovirimat,Brincidofovir,Vaccinia Immune Globulin